Sanofi SA announced it would be cutting insulin products by as much as 78% in the U.S., following the lead of other major pharmaceutical companies which are lowering prices at the behest of the Biden administration. Sanofi said that it would cap a Lantus patient’s monthly out-of-pocket cost at just $35. “No one should struggle to pay for their insulin,” Olivier Bogillot, Sanofi’s head of U.S. general medicines, told The Wall Street Journal.
